CAR-Engineered Astrocytes in Alzheimer’s Models
Preclinical findings show engineered astrocytes reduce amyloid buildup in mouse models and demonstrate a potential therapeutic approach
-
1
Researchers engineered astrocytes to express chimeric antigen receptors for targeted clearance of amyloid-β in Alzheimer’s models.
-
2
CAR-expressing astrocytes enhanced amyloid-β clearance in vitro and reduced plaque burden in mouse models.
-
3
This approach is designed as a self-sustaining system, avoiding the need for repeated dosing associated with current therapies.
-
4
Different CAR designs produced distinct biological effects, allowing for tailored CAR signaling to achieve specific therapeutic goals.
-
5
Further research is needed to assess safety and translation to humans, but CAR technologies show promise for neurodegenerative disorders.
